Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Age As a Predictor of Tolerance with Ovarian Cancer

Gynecol Oncol; ePub 2017 Jan 10; Gillen, et al

Although older patients with ovarian cancer are less likely to enroll on clinical trial, women aged ≥70 years tolerated chemotherapy on trial as well as their younger counterparts, a recent study found. This retrospective cohort study included 336 patients (23.5% ≥70 years) with ovarian cancer enrolled in front line chemotherapy trials between 2000 and 2013. Patients were stratified by age: <70 and ≥70 years. Researchers found:

  • Patients ≥70 years completed a comparable number of chemotherapy cycles compared to those <70 years, with similar number of dose modifications and delays.
  • Both hematologic and non-hematologic toxicities occurred at similar rates.
  • Age ≥70 years (HR, 1.8), stage III/IV (HR, 3.44), and residual disease (HR, 2.63) were independently predictive of shorter overall survival.


Gillen J, Gunderson C, Greenwade M, et al. Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. [Published online ahead of print January 10, 2017]. Gynecol Oncol. doi:10.1016/j.ygyno.2016.12.023.